Curis, Inc. (NASDAQ:CRIS) stock remained 10.72% volatile in recent week and indicated 8.83% volatility in last month. The Company’s beta coefficient sits at 1.3. Beta factor measures the amount of market risk associated with market trade. Higher the beta discloses more riskiness and lower the beta lower the risk. ATR value of 0.05 measure stock volatility. The Average True Range is an exponential moving average (14-days) of the True Ranges.
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, recently reported that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development. In this newly created role, Dr. Martell, a practicing oncologist and experienced drug developer, will directly manage the day-to-day operations of the Curis clinical development and research efforts. Dr. Martell is a member of the Board of Directors of Curis, and will resign from his board duties simultaneous with his start date on June 1st.
Ali Fattaey, Ph.D., President and Chief Executive Officer of Curis commented “Dr. Martell’s expertise and extensive experience as a drug developer in the biotech and pharma industry, and his passion as a treating oncologist is invaluable to our mission of developing our novel drug candidates for treating patients with cancer. His contributions to Curis as a board member over the last several years have convinced us that his expertise will now be instrumental as we have committed to the pivotal development of fimepinostat for patients with DLBCL, as well as advancing all our drug candidates through their respective trials”.
The company also announced the retirement of Dr. David Tuck, Chief Medical Officer, who will be leaving Curis in August to return to academic clinical research. “We want to thank Dr. Tuck for his valuable contribution to transforming Curis into a genuine clinical development organization with bringing multiple drug candidates into the clinic, including the first oral, small molecule inhibitor of immune checkpoints, CA-170, and the IRAK4 kinase inhibitor, CA-4948, both of which are continuing in their respective clinical trials. We wish David the best in his continued pursuit of academic excellence, and look to continue working with him as an advisor to Curis” said Ali Fattaey.
Curis, Inc. (CRIS) stock has performed -3.93% and it registered share value at $0.44 in Thursday trading session. At present, the stock price sited at -80.71% from the 52 week high and situated at -2.69% from 52 week low. 1631376 shares traded on hands while it’s an average volume stands with 2160.07K shares.
PROFITABILITY RATIOS: Gross Margin is observed at 95.00% and Return on Assets (ROA) an indicator of how profitable a company is relative to its total assets, is -68.70%. Return on Equity (ROE) is -247.40% and Return on Investment (ROI) is -75.90%.
Curis, Inc. (CRIS) has year to date performance of -37.44% and weekly performance of -20.37%. The stock has been moved at -50.55% over the last six months and -74.39% throughout last twelve months. The stock has performed -19.03% around last thirty days, and changed -12.26% over the last three months.